Last $0.12 USD
Change Today -0.034 / -22.09%
Volume 85.6K
ULGX On Other Exchanges
Symbol
Exchange
OTC US
As of 5:20 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

urologix inc (ULGX) Snapshot

Open
$0.14
Previous Close
$0.15
Day High
$0.14
Day Low
$0.11
52 Week High
09/17/13 - $0.35
52 Week Low
07/31/14 - $0.07
Market Cap
2.6M
Average Volume 10 Days
29.6K
EPS TTM
$-0.27
Shares Outstanding
21.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UROLOGIX INC (ULGX)

Related News

No related news articles were found.

urologix inc (ULGX) Related Businessweek News

No Related Businessweek News Found

urologix inc (ULGX) Details

Urologix, Inc. develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from benign prostatic hyperplasia (BPH). The company offers Cooled ThermoTherapy product line, which includes the CoolWave and Targis Control Units, and the CTC Advance catheter for the production of targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. It also distributes Prostiva RF Therapy Systems, which delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra and relieves BPH voiding symptoms. The company distributes its products to urologist offices, ambulatory surgery centers, and hospitals through its direct sales force and local distributors in the United States and internationally. Urologix, Inc was founded in 1991 and is based in Minneapolis, Minnesota.

urologix inc (ULGX) Top Compensated Officers

Chief Executive Officer, Interim Chief Financ...
Total Annual Compensation: $200.0K
Executive Vice President of Sales and Marketi...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2013.

urologix inc (ULGX) Key Developments

Urologix, Inc. Announces Executive Changes

On August 13, 2014, Brian J. Smrdel, the Urologix, Inc.' s Chief Financial Officer, tendered his resignation to the company effective as of that date. On August 13, 2014, the Board of Directors appointed Gregory J. Fluet as the company's Interim Chief Financial Officer and Principal Financial Officer. Mr. Fluet has served as a Director of the company and as the company' s Chief Executive Officer since January 25, 2013.

Urologix, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended June 30, 2014; Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2014; Provides Earnings Guidance for the Full Year 2015

Urologix, Inc. reported unaudited earnings results for the fourth quarter and year ended June 30, 2014. For the quarter, the company reported sales of $3.294 million compared to $4.184 million a year ago. Operating loss was $3.408 million compared to $1.282 million a year ago. Loss before income taxes was $3.587 million compared to $1.281 million a year ago. Net loss was $3.525 million or $0.17 per basic and diluted share compared to $1.247 million or $0.06 per basic and diluted share a year ago. The sequential decrease in revenue was driven primarily by reduced sales of Cooled ThermoTherapy(TM) (CTT) products partially offset by a slight increase in Prostiva(R) products. The year-over-year decline in revenue was driven by a decline in sales of CTT and Prostiva products compared to the prior year. For the year, the company reported sales of $14.235 million compared to $16.59 million a year ago. Operating loss was $6.93 million compared to $3.922 million a year ago. Loss before income taxes was $7.624 million compared to $4.278 million a year ago. Net loss was $7.608 million or $0.36 per basic and diluted share compared to $4.292 million or $0.21 per basic and diluted share a year ago. The year-over-year decline in revenue was driven by similar declines in sales of Cooled ThermoTherapy (CTT) products and Prostiva Radio Frequency (RF) Therapy products. Net cash used for operating activities was $1.53 million against $1.959 million a year ago. Purchases of property and equipment was $0.032 million against $0.079 million a year ago. For the quarter, the company recorded impairment of goodwill of $3.036 million. For the full year 2015, the company expects to generate positive cash flow from operations.

Urologix, Inc., Q4 2014 Earnings Call, Aug 19, 2014

Urologix, Inc., Q4 2014 Earnings Call, Aug 19, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULGX:US $0.12 USD -0.034

ULGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $12.22 USD -0.12
Medifocus Inc C$0.13 CAD +0.01
Olympus Corp ¥3,880 JPY 0.00
Uroplasty Inc $2.47 USD +0.0899
View Industry Companies
 

Industry Analysis

ULGX

Industry Average

Valuation ULGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROLOGIX INC, please visit www.urologix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.